An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma

Background: Despite advances in uveal melanoma (UM) diagnosis and treatment, about 50% of patients develop distant metastases, thereby displaying poor overall survival. Molecular profiling has identified several genetic alterations that can stratify patients with UM into different risk categories. H...

Full description

Saved in:
Bibliographic Details
Published in:Biomolecules (Basel, Switzerland) Switzerland), 2025-01, Vol.15 (1), p.146
Main Authors: Massimino, Michele, Tirrò, Elena, Stella, Stefania, Tomarchio, Cristina, Di Bella, Sebastiano, Vitale, Silvia Rita, Conti, Chiara, Puglisi, Marialuisa, Di Crescenzo, Rosa Maria, Varricchio, Silvia, Merolla, Francesco, Broggi, Giuseppe, Martorana, Federica, Turdo, Alice, Gaggianesi, Miriam, Manzella, Livia, Russo, Andrea, Stassi, Giorgio, Caltabiano, Rosario, Staibano, Stefania, Vigneri, Paolo
Format: Article
Language:English
Subjects:
Biomarkers
Cancer
Chromosome aberrations
Chromosomes
Comparative analysis
FOXO1 protein
Genetic analysis
Genomes
Melanoma
Metastases
Metastasis
Mutation
p53 Protein
Patients
Performance evaluation
Software
Survival
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Despite advances in uveal melanoma (UM) diagnosis and treatment, about 50% of patients develop distant metastases, thereby displaying poor overall survival. Molecular profiling has identified several genetic alterations that can stratify patients with UM into different risk categories. However, these genetic alterations are currently dispersed over multiple studies and several methodologies, emphasizing the need for a defined workflow that will allow standardized and reproducible molecular analyses. Methods: Following the findings published by “The Cancer Genome Atlas–UM” (TCGA-UM) study, we developed an NGS-based gene panel (called the UMpanel) that classifies mutation sets in four categories: initiating alterations (CYSLTR2, GNA11, GNAQ and PLCB4), prognostic alterations (BAP1, EIF1AX, SF3B1 and SRSF2), emergent biomarkers (CDKN2A, CENPE, FOXO1, HIF1A, RPL5 and TP53) and chromosomal abnormalities (imbalances in chromosomes 1, 3 and 8). Results: Employing commercial gene panels, reference mutated DNAs and Sanger sequencing, we performed a comparative analysis and found that our methodological approach successfully predicted survival with great specificity and sensitivity compared to the TCGA-UM cohort that was used as a validation group. Conclusions: Our results demonstrate that a reproducible NGS-based workflow translates into a reliable tool for the clinical stratification of patients with UM.
ISSN:2218-273X
2218-273X
DOI:10.3390/biom15010146